A miniature bird sculpted out of burnt bone in China about 13,500 years ago is the oldest known figurine from East Asia, researchers who discovered it in a refuse heap near an archeological site said.
The carefully crafted depiction of a songbird on a pedestal — smaller than an almond kernel — was found among burnt animal remains and fragments of ceramics at Lingjing in north ce ntral Henan Province, an area thought to have been home to some of China’s earliest civilizations.
The figurine is the “oldest known carving from East Asia,” said Francesco D’Errico of the University of Bordeaux, who coauthored the research published in the journal PLOS One on Wednesday.
Photo: AFP / CNRS / University of Bergen / Francesco D‘E’rrico / L. Doyon
“It shows that in this region sculpture starts at least 13,500 years ago and fills in a gap in our knowledge about the origin of art in this vast region,” he said.
The tiny carving was discovered by lead author Li Zhanyang (李占陽) of Shandong University, who has been excavating parts of the Lingjing site since 2005. Digging in the area had already revealed 11 distinct layers, ranging in age from 120,000 years ago to the Bronze Age.
Most of the fifth layer had been removed during a well-digging operation in 1958 and disposed of at a refuse heap nearby.
Photo: AFP / CNRS / University of Bergen / Francesco D‘E’rrico / L. Doyon
That dumping area was still intact years later, and when the authors sifted through the soil they found several artifacts, including pottery shards, burned animal remains and the bird figurine.
The carving is just 19.2mm long, 5.1mm wide and 12.5mm high.
Researchers were unable to use radiocarbon dating on the bird itself because the process would have damaged it, but they dated similar bones found with it, including one gouged using the same technique.
In this way they estimated the age of the bird figurine to be 13,500 years, which they said predates previously known figurines from this region by almost 8,500 years.
D’Errico said the bird was “exceptionally” well preserved, enabling researchers to trace the various carving methods used to create different parts of the figure, including gouging with a stone tool, scraping and polishing.
“Our observations show that the artist knew well which technique was the more adapted to carve the different parts of the animal,” he said.
“What is also remarkable is that the carving is not a fully realistic representation of a bird,” he said.
The figurine has an oversized tail, allowing it to balance on its pedestal.
“Without this trick the bird would fall on its head,” D’Errico said, adding that this shows the carving is not just a “casual experiment.”
The authors said that the craftsmanship suggests the advanced stage of an artistic tradition, which began much earlier.
In recent years, cave paintings in the Indonesian islands of Borneo and Sulawesi have been dated as more than 40,000 years old, suggesting ancient societies with advanced artistic cultures in the region.
While 3D portable art has been documented in Europe dating back about 40,000 years, the researchers said the Lingjing bird was the oldest such example found in East Asia.
Palaeolithic hunter-gatherers in China are known to have manufactured bone tools, such as spear points and needles, as well as personal ornaments made of shells, ostrich eggs and animal teeth, D’Errico said.
“The carving of objects with no apparent functional purpose, requiring a dedicated apprenticeship to be made, opens a new window on these societies,” he added.
The COVID-19 variant discovered in South Africa can “break through” Pfizer-BioNTech’s COVID-19 vaccine to some extent, a real-world data study released on Saturday found, although its prevalence in the country is low and the research has not been peer reviewed. The study in Israel compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated people with the disease. It matched age and gender, among other characteristics. The South African variant, B.1.351, was found to make up about 1 percent of all the COVID-19
RARE ADMISSION: A top Chinese expert was the first to publicly address the efficacy of the nation’s vaccines as it aims to inoculate 40 percent of its population by June China is considering mixing different COVID-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert told a conference in Chengdu on Saturday. Authorities have to “consider ways to solve the issue that efficacy rates of existing vaccines are not high,” Chinese media outlet The Paper reported, citing Chinese Center for Disease Control and Prevention Director Gao Fu (高福). His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country’s vaccines, as China forges ahead in its mass vaccination campaign and exports its jabs around the world. China
The Australian government yesterday said that it had decided against buying the single-dose Johnson & Johnson (J&J) COVID-19 vaccine and identified a second case of a rare blood clot likely linked to the AstraZeneca shot. The Australian government had been in talks with the New Jersey-based pharmaceutical giant, which had asked the Australian Therapeutic Goods Administration for provisional registration. However, Australian Minister of Health Greg Hunt ruled out a J&J contract, because its vaccine was similar to the AstraZeneca product, which Australia had already contracted for 53.8 million doses. Hunt said the government was following the advice of Australia’s scientific and technical advisory
The Indonesian government has said it is satisfied with the effectiveness of the Chinese COVID-19 vaccine it has been using, after China’s top disease control official said that current vaccines offer low protection against the novel coronavirus. Siti Nadia Tarmizi, a spokesperson for Indonesia’s COVID-19 vaccine program, on Monday said the WHO had found that the Chinese vaccines had met requirements by being more than 50 percent effective. Clinical trials in Indonesia for the vaccine from Chinese drugmaker Sinovac showed that it was 65 percent effective, she said. “It means ... the ability to form antibodies in our bodies is still very
RSS